Healthcare Market News (News) October 1999 The National Institute for Clinical Excellence (NICE) has recommended that the flu drug Relenza, developed by Glaxo Wellcome, should not be made available on the NHS. Relenza is the first drug to be subjected to appraisal by NICE. Andrew Dillon, chief executive of NICE, said: ‘The Institute’s guidance to…
About LaingBuisson
LaingBuisson has been serving clients for over 30 years with insights, analysis and data on market structures, policy and strategy across healthcare, social care and education.
Contact us: [email protected]
Follow LaingBuisson
©2023 All rights reserved LaingBuisson 
